| Literature DB >> 27362763 |
Yulia Surova1,2, Björn Lampinen3, Markus Nilsson4, Jimmy Lätt5, Sara Hall1,2, Håkan Widner1,2, Danielle van Westen1,4, Oskar Hansson6,7.
Abstract
In Parkinson's disease (PD), pathological microstructural changes occur and such changes might be detected using diffusion magnetic resonance imaging (dMRI). However, it is unclear whether dMRI improves PD diagnosis or helps differentiating between phenotypes, such as postural instability gait difficulty (PIGD) and tremor dominant (TD) PD. We included 105 patients with PD and 44 healthy controls (HC), all of whom underwent dMRI as part of the prospective Swedish BioFINDER study. Diffusion kurtosis imaging (DKI) and neurite density imaging (NDI) analyses were performed using regions of interest in the basal ganglia, the thalamus, the pons and the midbrain as well as tractography of selected white matter tracts. In the putamen, the PD group showed increased mean diffusivity (MD) (p = .003), decreased fractional anisotropy (FA) (p = .001) and decreased mean kurtosis (MK), compared to HC (p = .024). High MD and a low MK in the putamen were associated with more severe motor and cognitive symptomatology (p < .05). Also, patients with PIGD exhibited increased MD in the putamen compared to the TD patients (p = .009). In the thalamus, MD was increased (p = .001) and FA was decreased (p = .032) in PD compared to HC. Increased MD and decreased FA correlated negatively with motor speed and balance (p < .05). In the superior longitudinal fasciculus (SLF), MD (p = .019) and fiso were increased in PD compared to HC (p = .03). These changes correlated negatively with motor speed (p < .002) and balance (p < .037). However, most of the observed changes in PD were also present in cases with either multiple system atrophy (n = 11) or progressive supranuclear palsy (n = 10). In conclusion, PD patients exhibit microstructural changes in the putamen, the thalamus, and the SLF, which are associated with worse disease severity. However, the dMRI changes are not sufficiently specific to improve the diagnostic work-up of PD. Longitudinal studies should evaluate whether dMRI measures can be used to track disease progression.Entities:
Mesh:
Year: 2016 PMID: 27362763 PMCID: PMC4928807 DOI: 10.1371/journal.pone.0157755
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Parameter maps for both PD patients and healthy controls with key ROIs examined.
ROIs for measurement in the anatomical areas reported in Table 2, overlaid on the FA, b0, MK and MD maps from a 66-year-old healthy male participant (panels a-e), and a 66-year-old male PD patient (panels f-j). In panels (a) and (f), ROIs are placed in the pallidum and the thalamus (right), and the putamen (left) on the FA-map; in panels (b) and (g) in the substantia nigra and red nucleus (right) on the b0-map; in panels (c) and (h) in the caudate head (right) on the MK map; and in panels (d) and (i) in the pons and midbrain on the MD map.
Diffusion magnetic resonance measures in patients with Parkinson’s disease (PD) and healthy controls (HC).
The PD group was also divided into those with postural instability and gait difficulty (PIGD) and tremor-dominant (TD) phenotypes.
| Structure | Parameter | HC (n = 44) | PD (n = 105) | PIGD (n = 47) | TD (n = 50) | ||
|---|---|---|---|---|---|---|---|
| Substantia nigra | FA | 0.64 ± 0.10 | 0.62 ± 0.11 | 0.571 | 0.62 ± 0.1 | 0.62 ± 0.11 | 0.971 |
| Caudate head | FA | 0.23 ± 0.04 | 0.22 ± 0.04 | 0.390 | 0.22 ± 0.03 | 0.23 ± 0.04 | 0.170 |
| Putamen | FA | 0.23 ± 0.04 | 0.20 ± 0.03 | 0.20 ± 0.33 | 0.21 ± 0.03 | 0.170 | |
| Thalamus | FA | 0.37 ± 0.02 | 0.36 ± 0.02 | 0.36 ± 0.02 | 0.36 ± 0.02 | 0.683 | |
| Pons | FA | 0.52 ± 0.02 | 0.51 ± 0.02 | 0.524 | 0.51 ± 0.03 | 0.51 ± 0.02 | 0.829 |
| Substantia nigra | MD | 0.45 ± 0.12 | 0.48 ± 0.12 | 0.251 | 0.49 ± 0.1 | 0.48 ± 0.12 | 0.885 |
| Caudate head | MD | 0.80 ± 0.12 | 0.83 ± 0.14 | 0.138 | 0.84 ± 0.15 | 0.82 ± 0.14 | 0.269 |
| Putamen | MD | 0.78 ± 0.10 | 0.80 ± 0.14 | 0.88 ± 0.17 | 0.81 ± 0.10 | ||
| Thalamus | MD | 0.77 ± 0.05 | 0.80 ± 0.05 | 0.82 ± 0.05 | 0.80 ± 0.05 | 0.052 | |
| Pons | MD | 0.70 ± 0.04 | 0.71 ± 0.05 | 0.165 | 0.71 ± 0.05 | 0.70 ± 0.05 | 0.549 |
| Substantia nigra | MK | ND | ND | ND | ND | ||
| Caudate head | MK | 0.92 ± 0.11 | 0.95 ± 0.11 | 0.253 | 0.94 ± 0.10 | 0.94 ± 0.11 | 0.776 |
| Putamen | MK | 1.24 ± 0.19 | 1.16 ± 0.15 | 1.12 ± 0.13 | 1.18 ± 0.17 | 0.101 | |
| Thalamus | MK | 1.19 ± 0.09 | 1.16 ± 0.10 | 0.066 | 1.15 ± 0.10 | 1.17 ± 0.10 | 0.569 |
| Pons | MK | 1.52 ± 0.11 | 1.55 ± 0.15 | 0.238 | 1.53 ± 0.15 | 1.57 ± 0.16 | 0.356 |
| Substantia nigra | NDI | ND | ND | ND | ND | ||
| Caudate head | NDI | 0.66 ± 0.08 | 0.62 ± 0.15 | 0.168 | 0.60 ± 0.15 | 0.63 ± 0.16 | 0.330 |
| Putamen | NDI | 0.77 ± 0.13 | 0.74 ± 0.12 | 0.119 | 0.73 ± 0.11 | 0.74 ± 0.12 | 0.762 |
| Thalamus | NDI | 0.72 ± 0.07 | 0.72 ± 0.07 | 0.874 | 0.72 ± 0.07 | 0.73 ± 0.07 | 0.423 |
| Pons | NDI | 0.94 ± 0.05 | 0.95 ± 0.04 | 0.123 | 0.95 ± 0.04 | 0.95 ± 0.04 | 0.979 |
| Substantia nigra | NDI | ND | ND | ND | ND | ||
| Caudate head | NDI | ± 0.08 | 0.10 ± 0.08 | 0.038 | 0.01 ± 0.09 | 0.01 ± 0.08 | 0.539 |
| Putamen | NDI | 0.11 ± 0.08 | 0.12 ± 0.09 | 0.987 | 0.13 ± 0.11 | 0.11 ± 0.08 | 0.569 |
| Thalamus | NDI | 0.09 ± 0.04 | 0.11 ± 0.03 | 0.024 | 0.11 ± 0.04 | 0.10 ± 0.03 | 0.784 |
| Pons | NDI | 0.10 ± 0.03 | 0.11 ± 0.03 | 0.122 | 0.11 ± 0.03 | 0.11 ± 0.03 | 0.445 |
MD [10^-9 m^2/s]. Values are given as mean ± SD. FA, fractional anisotropy; MD, mean diffusivity; MK, mean kurtosis; NDI fiso and fic, neurite density imaging measures; ND, not done.
a p, Mann-Whitney U test.
b p < .05, ANCOVA (age/gender adjusted).
c p < .05, ANCOVA (age adjusted).
P-values given in bold were significant when both using Mann-Whitney U test and ANCOVA.
Demographic data and biomarker levels for the diagnostic groups.
| HC (n = 44) | PD (n = 105) | PIGD (n = 47) | TD (n = 50) | |||
|---|---|---|---|---|---|---|
| Gender female: male | 25: 19 | 61: 44 | 0.02 | 20:27 | 15:35 | 0.07 |
| Age (years) | 66 ± 8 | 66 ± 11 | 0.475 | 66 ± 11 | 66 ±11 | 0.767 |
| Disease duration (years) | ND | 5 ± 4 | 5 ± 5 | 5 ± 3 | 0.266 | |
| Hoehn and Yahr stage | ND | 2 ± 1 | 2 ± 1 | 2 ± 1 | 0.001 | |
| Schwab and England | 100 | 90 ± 9 | <0.001 | 87 ± 11 | 93 ± 6 | 0.001 |
| UPDRS-III motor score | 2 ± 2 | 13 ± 10 | <0.001 | 13 ± 11 | 13 ± 8 | 0.734 |
| Tandem gait test “on” | 0.21 ± 0.5 | 0.66 ± 1 | 0.006 | 0.96 ± 1.2 | 0.34 ± 0.6 | 0.005 |
| Timed up and go test “on” (seconds) | 8 ± 1 | 10 ± 2 | <0.00 | 10 ± 3 | 9 ± 2 | 0.031 |
| MMSE score | 28 ± 2 | 28 ± 2 | 0.887 | 28 ± 2 | 28 ± 1 | 0.731 |
| Memory delayed recall (ADAS-Cog) | 2 ± 2 | 4 ± 7 | 0.031 | 3 ± 3 | 3 ± 2 | 0.901 |
| AQT | 61 ± 14 | 70 ± 18 | 0.011 | 73 ± 22 | 67 ± 15 | 0.024 |
Values are given as mean ±SD. UPDRS-III, Unified Parkinson’s disease rating scale motor part; MMSE, Mini Mental State Examination test; ADAS-Cog, Alzheimer's Disease Assessment Scale; AQT, the Quick Test of Cognitive Speed (AQT) test; HC, healphy controls; PD, Parkinson’s disease; PIGD, postural instability gait difficulty; TD, tremor dominant; SD, standard deviation; ND, not done.
a Pearson’s chi-square
b Mann-Whitney U test.
Diffusion kurtosis imaging measures in white matter structures in patients with Parkinson’s disease (PD) and healthy controls (HC).
| Region | Parameter | HC (n = 44) | PD (n = 105) | |
|---|---|---|---|---|
| Cingulum anterior | FA | 0.35 ± 0.03 | 0.34 ± 0.05 | 0.927 |
| Cingulum posterior | FA | 0.49 ± 0.03 | 0.49 ± 0.03 | 0.987 |
| Cingulum hippocampus | FA | 0.38 ± 0.03 | 0.40 ± 0.04 | 0.041 |
| Fornix | FA | 0.30 ± 0.04 | 0.30 ± 0.04 | 0.753 |
| Corpus callosum | FA | 0.55 ± 0.03 | 0.56 ± 0.04 | 0.280 |
| SLF | FA | 0.46 ± 0.03 | 0.46 ± 0.03 | 0.731 |
| ILF | FA | 0.45 ± 0.04 | 0.44 ± 0.05 | 0.070 |
| IFOF | FA | 0.51 ± 0.03 | 0.50 ± 0.08 | 0.148 |
| Uncinate Fasciculus | FA | 0.39 ± 0.03 | 0.39 ± 0.03 | 0.224 |
| CST | FA | 0.40 ± 0.12 | 0.38 ± 0.13 | 0.141 |
| Cingulum anterior | MD | 0.90 ± 0.05 | 0.89 ± 0.10 | 0.874 |
| Cingulum posterior | MD | 0.80 ± 0.04 | 0.81 ± 0.05 | 0.208 |
| Cingulum hippocampus | MD | 0.87 ± 0.07 | 0.88 ± 0.07 | 0.728 |
| Fornix | MD | 1.75 ± 0.24 | 1.73 ± 0.25 | 0.744 |
| Corpus callosum | MD | 1.26 ± 0.11 | 1.26 ± 0.12 | 0.698 |
| SLF | MD | 0.81 ± 0.05 | 0.84 ± 0.05 | |
| ILF | MD | 0.97 ± 0.10 | 0.99 ± 0.13 | 0.034 |
| IFOF | MD | 0.95 ± 0.06 | 0.95 ± 0.15 | 0.254 |
| Uncinate Fasciculus | MD | 0.91 ± 0.06 | 0.94 ± 0.07 | 0.063 |
| CST | MD | 0.68 ± 0.19 | 0.67 ± 0.24 | 0.057 |
| Cingulum anterior | MK | 0.84 ± 0.06 | 0.83 ± 0.10 | 0.914 |
| Cingulum posterior | MK | 1.09 ± 0.07 | 1.09 ± 0.08 | 0.607 |
| Cingulum hippocampus | MK | 1.00 ± 0.08 | 1.01 ± 0.09 | 0.275 |
| Fornix | MK | 0.77 ± 0.08 | 0.79 ± 0.07 | 0.179 |
| Corpus callosum | MK | 0.90 ± 0.06 | 0.91 ± 0.06 | 0.397 |
| SLF | MK | 1.18 ± 0.05 | 1.17 ± 0.06 | 0.234 |
| ILF | MK | 1.02 ± 0.06 | 1.00 ± 0.12 | 0.454 |
| IFOF | MK | 1.01 ± 0.04 | 1.00 ± 0.16 | 0.970 |
| Uncinate Fasciculus | MK | 1.03 ± 0.05 | 1.02 ± 0.06 | 0.379 |
| CST | MK | 1.16 ± 0.06 | 1.14 ± 0.14 | 0.429 |
MD [10^-9 m^2/s]. Values are given as mean ± SD. ILF, inferior longitudinal fasciculus; IFOF, inferior fronto-occipital fasciculus; SLF, superior longitudinal fasciculus; CST, corticospinal tract; FA, fractional anisotropy; MD, mean diffusivity; MK, mean kurtosis; NDI fiso and fic, neurite density imaging measures.
a p, Mann-Whitney U test.
b p < .05, ANCOVA (age and gender adjusted).
P-values given in bold were significant when both using Mann-Whitney U test and ANCOVA.
Neurite density imaging (NDI) measures in white matter structures in patients with Parkinson’s disease (PD) and healthy controls (HC).
| Region | Parameter | HC (n = 44) | PD (n = 105) | |
|---|---|---|---|---|
| Cingulum anterior | NDI | 0.58 ± 0.10 | 0.57 ± 0.07 | 0.340 |
| Cingulum posterior | NDI | 0.71 ± 0.12 | 0.72 ± 0.06 | 0.582 |
| Cingulum hippocampus | NDI | 0.72 ± 0.13 | 0.75 ± 0.07 | 0.658 |
| Fornix | NDI | 0.71 ± 0.09 | 0.72 ± 0.1 | 0.472 |
| Corpus callosum | NDI | 0.76 ± 0.13 | 0.76 ± 0.09 | 0.675 |
| SLF | NDI | 0.72 ± 0.04 | 0.70 ± 0.09 | 0.351 |
| ILF | NDI | 0.64 ± 0.05 | 0.62 ± 0.08 | 0.167 |
| IFOF | NDI | 0.65 ± 0.04 | 0.64 ± 0.08 | 0.184 |
| Uncinate Fasciculus | NDI | 0.64 ± 0.04 | 0.63 ± 0.06 | 0.225 |
| CST | NDI | 0.73 ± 0.04 | 0.71 ± 0.06 | |
| Cingulum anterior | NDI | 0.11 ± 0.03 | 0.10 ± 0.03 | 0.268 |
| Cingulum posterior | NDI | 0.10 ± 0.03 | 0.10 ± 0.03 | 0.484 |
| Cingulum hippocampus | NDI | 0.14 ± 0.04 | 0.14 ± 0.04 | 0.923 |
| Fornix | NDI | 0.50 ± 0.09 | 0.49 ± 0.11 | 0.724 |
| Corpus callosum | NDI | 0.29 ± 0.04 | 0.29 ± 0.05 | 0.690 |
| SLF | NDI | 0.11 ± 0.03 | 0.12 ± 0.03 | |
| ILF | NDI | 0.15 ± 0.04 | 0.16 ± 0.04 | 0.134 |
| IFOF | NDI | 0.14 ± 0.03 | 0.15 ± 0.03 | 0.226 |
| Uncinate Fasciculus | NDI | 0.13 ± 0.03 | 0.14 ± 0.03 | 0.112 |
| CST | NDI | 0.11 ± 0.03 | 0.12 ± 0.03 | 0.060 |
Values are given as mean ± SD. ILF, inferior longitudinal fasciculus; IFOF, inferior fronto-occipital fasciculus; SLF, superior longitudinal fasciculus; CST, corticospinal tract; FA, fractional anisotropy; MD, mean diffusivity; MK, mean kurtosis; NDI fiso and fic, neurite density imaging measures.
a p, Mann-Whitney U test.
b p < .05, ANCOVA (age and gender adjusted). P-values given in bold were significant when both using Mann-Whitney U test and ANCOVA.
Fig 2Correlation between mean diffusivity (MD) in the putamen, thalamus and superior longitudinal fasciculus (SLF) with the time up and go test score and between the MD in the SLF with Unified Parkinson’s disease rating scale motor part (UPDRS-III) score.
A moderate positive correlation was found between MD in the putamen, thalamus and SLF and time up and go test score. A moderate positive correlation was found between the MD in the SLF and UPDRS-III scale score. Rs, Spearman’s rho.
Differences between patients with Parkinson's disease (PD) and cases with progressive supranuclear palsy (PSP) or multiple system atrophy (MSA).
| PD (n = 105) | PSP (n = 10) | MSA (n = 11) | |||
|---|---|---|---|---|---|
| Gender female: male | 44: 61 | 5: 5 | 5: 6 | 1.000 | 0.527 |
| Age (years) | 66 ± 11 | 73 ± 6 | 63 ± 10 | 0.037 | 0.302 |
| Disease duration (years) | 5 ± 4 | 7 ± 2 | 6 ± 4 | 0.051 | 0.299 |
| Hoehn and Yahr | 2 ± 1 | 4 ± 1 | 4 ± 1 | <0.001 | <0.001 |
| Schwab and England | 90 ± 9 | 58 ± 35 | 67 ± 22 | <0.002 | <0.001 |
| UPDRS-III motor score | 13 ± 10 | 39 ± 14 | 34 ± 19 | <0.001 | <0.001 |
| FA putamen | 0.20 ± 0.03 | 0.23 ± 0.06 | 0.26 ± 0.03 | 0.053 | |
| MD putamen | 0.80 ± 0.14 | 0.88 ± 0.33 | 0.83 ± 0.15 | 0.275 | 0.276 |
| MK putamen | 1.14 ± 0.15 | 1.35 ± 0.25 | 1.34 ± 0.17 | ||
| FA thalamus | 0.36 ± 0.02 | 0.34 ± 0.04 | 0.35 ± 0.01 | 0.204 | |
| MD thalamus | 0.80 ± 0.05 | 0.87 ± 0.11 | 0.84 ± 0.06 | 0.08 | |
| MD SLF | 0.84 ± 0.05 | 0.89 ± 0.09 | 0.84 ± 0.04 | 0.984 | |
| NDI | 0.71 ± 0.06 | 0.69 ± 0.07 | 0.71 ± 0.04 | 0.473 | 0.875 |
| NDI | 0.12 ± 0.03 | 0.12 ± 0.01 | 0.13 ± 0.04 | 0.164 | 0.638 |
MD [10^-9 m^2/s]. Values are given as mean ± SD. UPDRS-III, Unified Parkinson’s disease rating scale motor part; FA, fractional anisotropy; MD, mean diffusivity; DKI, Diffusion Tensor Imaging; dMRI, diffusion magnetic resonance imaging; SLF, superior longitudinal fasciculus; CST, corticospinal tract; NDI fiso and fic, neurite density imaging measures; SD, standard deviation.
a Pearson’s chi-square. p-value, Mann-Whitney U test.
b PD/PSP,
c PD/MSA,
p < .05, ANCOVA (age adjusted). P-values given in bold were significant when both using Mann-Whitney U test and ANCOVA.